CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China). With the acquisition, ...
Newsable Asianet News on MSN
Semaglutide generics' future depends on API capacity: Goldman Sachs
Goldman Sachs reports the future of semaglutide genericisation and GLP-1 pricing hinges on peptide API manufacturing capacity ...
The big unknown is whether CDMO capacity built for branded drugs gets diverted to generics, and whether SPPS can scale fast enough to meet a market Goldman models at ~99,000 kg of peptide API by 2030 ...
Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIs CordenPharma has entered into an agreement to acquire AmbioPharm, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results